View Older Stories

Jul 31, 2026 11:14AM Neurocrine Bio. (NBIX) PT Raised to $215 at Stifel

Jul 31, 2026 07:45AM Neurocrine Bio. (NBIX) PT Raised to $222 at Guggenheim

Jul 31, 2026 07:42AM Neurocrine Bio. (NBIX) PT Raised to $204 at Needham

Jul 30, 2026 04:19PM Neurocrine Biosciences (NBIX) Tops Q2 EPS by 127c ; Offers Guidance

Jul 23, 2026 04:06PM Neurocrine Biosciences names three senior vice presidents

Jul 21, 2026 04:06PM Neurocrine Biosciences names Samir Siddhanti chief business officer

Jul 13, 2026 07:41AM Neurocrine Bio. (NBIX) PT Raised to $200 at Truist Securities

Jul 13, 2026 07:34AM Neurocrine Bio. (NBIX) PT Raised to $170 at BMO Capital

Jun 22, 2026 09:29AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Jun 15, 2026 04:11PM Neurocrine Biosciences (NBIX) Presents New VYKAT XR (diazoxide choline) Data

Jun 15, 2026 04:06PM Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY

Jun 15, 2026 08:36AM Neurocrine presents two-year CRENESSITY data showing growth improvements

Jun 15, 2026 08:30AM Neurocrine shows two-year CRENESSITY data at ENDO 2026 medical meeting

Jun 8, 2026 04:05PM Neurocrine presents tardive dyskinesia treatment data at conference

Jun 8, 2026 08:31AM Neurocrine presents INGREZZA data for tardive dyskinesia patients

Jun 5, 2026 08:59AM Morgan Stanley tracks prescription trends for US neurology drugs

Jun 3, 2026 08:31AM Neurocrine to present two-year CRENESSITY data at medical meeting

Jun 2, 2026 05:07AM Goldman Sachs Resumes Neurocrine Bio. (NBIX) at Buy

May 21, 2026 04:37PM Bernstein SocGen Group Starts Neurocrine Bio. (NBIX) at Outperform

May 18, 2026 04:06PM Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia

May 6, 2026 01:16PM Neurocrine Bio. (NBIX) PT Raised to $155 at Truist Securities

May 6, 2026 08:32AM Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY

May 6, 2026 06:33AM Neurocrine Bio. (NBIX) PT Raised to $176 at Wedbush

May 6, 2026 06:12AM Neurocrine Bio. (NBIX) PT Raised to $230 at Oppenheimer

May 5, 2026 04:14PM Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue

May 1, 2026 04:06PM Neurocrine shows sustained pediatric results for CRENESSITY in two-year study

Apr 29, 2026 04:07PM Neurocrine publishes tardive dyskinesia scale validation research

Apr 22, 2026 04:05PM Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients

Apr 14, 2026 08:32AM INGREZZA shows higher treatment persistence than AUSTEDO XR in study

Apr 10, 2026 06:06AM Neurocrine Bio. (NBIX) PT Raised to $185 at Morgan Stanley

Apr 8, 2026 07:13AM Neurocrine Bio. (NBIX) PT Raised to $215 at H.C. Wainwright

Apr 7, 2026 05:01AM Neurocrine Bio. (NBIX) PT Raised to $242 at Citi

Apr 6, 2026 03:49PM Neurocrine Bio. (NBIX) PT Raised to $166 at Wedbush

Apr 6, 2026 02:41PM Neurocrine Bio. (NBIX) PT Raised to $200 at Canaccord

Apr 6, 2026 01:59PM Neurocrine Bio. (NBIX) PT Raised to $220 at Oppenheimer on SLNO deal

Apr 6, 2026 01:10PM Baird on Neurocrine Bio's Soleno deal: Incrementally positive on acquisition

Apr 6, 2026 09:35AM UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX) Following Reports of Soleno Acquisition

Apr 6, 2026 05:53AM Neurocrine Biosciences nearing over $2.5B deal for Soleno Therapeutics

Mar 26, 2026 08:33AM Neurocrine presents tardive dyskinesia treatment guidance for elderly

Mar 17, 2026 04:09PM Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer

Mar 10, 2026 09:22AM Neurocrine Bio. (NBIX) PT Raised to $195 at Cantor Fitzgerald on Ingrezza Outlook

Feb 24, 2026 09:07AM Wolfe Research Starts Neurocrine Bio. (NBIX) at Outperform

Feb 24, 2026 08:53AM RBC Capital: 'We see upside in multiple scenarios, and so would remain buyers'

Feb 17, 2026 09:45AM Neurocrine Bio. (NBIX) PT Lowered to $140 at Truist Securities

Feb 17, 2026 09:27AM Neurocrine Bio. (NBIX) PT Lowered to $140 at BMO Capital

Feb 12, 2026 07:26AM Canaccord Genuity Reiterates Buy Rating on Neurocrine Bio. (NBIX)

Feb 12, 2026 07:11AM Neurocrine Bio. (NBIX) PT Lowered to $192 at H.C. Wainwright

Feb 11, 2026 04:04PM Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c ; Offers Guidance

Jan 30, 2026 10:08AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX), Optimistic on Ingrezza

Jan 15, 2026 08:32AM Neurocrine presents data showing INGREZZA achieved higher target occupancy

View Older Stories